Victor Abler

TL;DR: A clinically meaningful benefit to rasagiline is indicated in terms of the magnitude of improvement in parkinsonian symptoms for those with the favourable response genotypes.

TL;DR: This follow-up study aimed to assess whether benefits of early‐start treatment with rasagiline 1 mg/day versus delayed‐ start treatment in PD persist and the clinical progression rate during long‐term naturalistic treatment.

TL;DR: There are opportunities to improve the landscape of LBD clinical trials by harmonizing clinical assessments and biomarkers across cohorts and research studies, developing and validating outcome measures in LBD, engaging the patient community to assess research needs and priorities, and incorporating biomarker and genotype profiling in study design.

TL;DR: An international meeting involving leaders in the field and MSA advocacy groups was convened in Las Vegas, Nevada, to identify critical research areas where consensus and progress was needed to improve understanding, diagnosis, and treatment of the disease.

TL;DR: Despite a lower TD prevalence than previously estimated and the predominant use of atypical antipsychotics, identified TD patients appear to have a substantial comorbidity burden that requires special treatment and management consideration.